NSTEMI standing orders

For UA/NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to initiate antiplatelet therapy with both clopidogrel (loading dose followed by daily maintenance dose) and a GP IIb/IIIa inhibitor (Class IIa, LOE: B). ................
................